United Nations & Merck & Co.

United Nations: The United Nations>>> has mobilized emergency support and released funds to accelerate the Ebola response in the Democratic Republic of the Congo>>> and the region, providing logistical assistance and aid.

Merck & Co.: Merck & Co.>>>'s Ervebo vaccine, effective against the Zaire strain of Ebola, is being considered for potential use against the Uganda — Bundibugyo strain, though its efficacy is still under assessment.

United Nations: The United Nations humanitarian office reported that almost a million people have been displaced from their homes by conflict in Democratic Republic of the Congo — Ituri Province, contributing to the challenges of the Ebola response.

Merck & Co.: Merck & Co. is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

United Nations: The United Nations released $60 million from its Central Emergency Response Fund to accelerate the response to the Ebola outbreak in the region, providing crucial financial support.

Merck & Co.: Merck & Co.'s approved vaccine Ervebo for the Zaire strain of Ebola is referenced as a technological precedent for IAVI's Bundibugyo vaccine candidate.